대한골관절종양학회지 (The Journal of the Korean bone and joint tumor society)

  • 제18권1호
  • /
  • Pages.20-27
  • /
  • 2012
  • /
  • 1226-4962(pISSN)
  • /
  • 2233-9841(eISSN)
대한근골격종양학회 (The Korean Musculoskeletal Tumor Society)
권호 표지
DOI QR코드

DOI QR Code

골육종의 조직학적 등급에 따른 CXCR4 발현 및 예후로서의 의미

Differential Expression of CXCR4 in Conventional High-grade and Low-grade Central Osteosarcoma and Its Prognostic Implications

  • 박혜림 (한림대학교 의과대학 병리학교실) ;
  • 서진원 (한림대학교 의과대학 병리학교실) ;
  • ;
  • ;
  • 박용구 (경희대학교 의과대학 병리학교실)
  • Park, Hye-Rim (Department of Pathology, Hallym University College of Medicine) ;
  • Seo, Jin-Won (Department of Pathology, Hallym University College of Medicine) ;
  • Bacchini, Patrizia (Servizio di Anatomia Pathologica, Istituto Ortopedico Rizzoli) ;
  • Bertoni, Franco (Servizio di Anatomia Pathologica, Istituto Ortopedico Rizzoli) ;
  • Park, Yong-Koo (Department of Pathology, Kyung Hee University College of Medicine)
  • 투고 : 2011.10.22
  • 심사 : 2012.06.13
  • 발행 : 2012.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목적: 케모카인 수용체인 CXCR4는 암에서 발현되며 암의 전이에 관여한다고 알려져 있다. 저자들은 통상적인 조직학적으로 고등급인 골육종과 저등급 중심부 골육종에서 CXCR4 발현을 비교하고 CXCR4 발현과 예후 간에 연관성이 있는지 살펴보았다. 대상 및 방법: 총 63명의 골육종 환자에서 CXCR4에 대한 면역조직화학검사를 시행하였고 임상적, 병리학적 인자 및 전체적인 생존율과의 연관성을 살펴보았다. 결과: CXCR4는 통상적인 고등급(조직학적 등급 3 및 4) 골육종의 76.3%에서 발현된 반면 저등급(조직학적 등급 1 및 2) 중심부 골육종의 36%에서 발현되었다. 또한 고등급 골육종의 47.4%에서 미만성으로 발현된 반면 모든 저등급 골육종은 병소에 국한되어 발현되었다. CXCR4 발현은 조직학적 등급과 통계학적으로 유의한 상관관계를 나타내었다(p<0.0001). 전체적인 생존률은 CXCR4 발현 증가(p=0.0058), 고등급의 조직학적 등급(p<0.0001), 어린 연령(p=0.0140)에 따라 유의하게 감소하였지만, 성별, 종양 크기, AJCC 병기와는 연관성이 뚜렷하지 않았다. 결론: CXCR4 발현은 골육종에서 고도의 조직학적 분화도가 나쁜 등급 및 불량한 예후와 연관된다.

Purpose: The chemokine receptor CXCR4 has been reported to be aberrantly expressed in human cancer and has been shown to participate in cancer metastasis. We compared the expression of CXCR4 in conventional high-grade and low-grade central osteosarcomas, and determined if an association between CXCR4 expression and prognosis could be made. Materials and Methods: We performed the immunohistochemistry for CXCR4 in a total of 63 patients with osteosarcoma and determined the relationships according to the clinicopathologic variables and overall survival rates. Results: CXCR4 was detected in 76.3% of conventional high-grade osteosarcoma patients and in 36% of low-grade central osteosarcomas. Diffuse expression was noted in 47.4% of the high-grade osteosarcomas and all low-grade cases were focal positive. CXCR4 expression was significantly correlated with histologic grade (p<0.0001). While overall survival rate was reduced significantly with increased CXCR4 expression (p=0.0058), higher histologic grade (p<0.0001), and younger age (p=0.0140), survival rate did not correlate with gender, tumor size, or AJCC stage. Conclusion: Our results suggest that CXCR4 expression is associated with higher-grade tumors and with poor prognosis for osteosarcoma patients.

키워드

참고문헌

  1. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokines grammar for immune cells. Annu Rev Immunol. 2004;22:891-928. https://doi.org/10.1146/annurev.immunol.22.012703.104543
  2. Oda Y, Yamamoto H, Tamiya S, et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol. 2006;19:738-45. https://doi.org/10.1038/modpathol.3800587
  3. Chinni SR, Yamamoto H, Dong Z, Sabbota A, Bonfi l RD, Cher ML. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res. 2008;6:446-57. https://doi.org/10.1158/1541-7786.MCR-07-0117
  4. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-6. https://doi.org/10.1038/35065016
  5. Spano JP, Andre F, Morat L, et al. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol. 2004;15:613-7. https://doi.org/10.1093/annonc/mdh136
  6. Scala S, Ottaiano A, Ascierto PA, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res. 2005;11:1835-41. https://doi.org/10.1158/1078-0432.CCR-04-1887
  7. Koishi K, Yoshikawa R, Tsujimura T, et al. Persistent CXCR4 expression aft er preoperative chemoradiotherapy predicts early recurrence and poor prognosis in esophageal cancer. World J Gastroenterol. 2006;12:7585-90. https://doi.org/10.3748/wjg.v12.i47.7585
  8. Jiang YP, Wu XH, Shi B, Wu WX, Yin GR. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. Gynecol Oncol. 2006;103:226-33. https://doi.org/10.1016/j.ygyno.2006.02.036
  9. Azenshtein E, Luboshits G, Shina S, et al. Th e CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res. 2002;62:1093-102.
  10. Fan TM, Barger AM, Fredrickson RL, Fitzsimmons D, Garrett LD. Investigating CXCR4 expression in canine appendicular osteosarcoma. J Vet Intern Med. 2008;22:602-8. https://doi.org/10.1111/j.1939-1676.2008.0089.x
  11. Laverdiere C, Hoang BH, Yang R, et al. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res. 2005;11:2561-7. https://doi.org/10.1158/1078-0432.CCR-04-1089
  12. Perissinotto E, Cavalloni G, Leone F, et al. Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res. 2005;11:490-7.
  13. Unni KK, Dahlin DC. Grading of bone tumors. Semin Diagn Pathol. 1984;1:165-72.
  14. Paoletti S, Borzi RM, Mazzetti I, et al. Human osteosarcoma cells release matrix degrading enzymes in response to chemokine activation. Int J Oncol. 2001;18:11-6.
  15. Libura J, Drukala J, Majka M, et al. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood. 2002;100:2597-606. https://doi.org/10.1182/blood-2002-01-0031
  16. Murakami T, Maki W, Cardones AR, et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res. 2002;62:7328-34.
  17. Smith MC, Luker KE, Garbow JR, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004;64:8604-12. https://doi.org/10.1158/0008-5472.CAN-04-1844
  18. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002;62:1832-7.
  19. Bai S, Wang D, Klein MJ, Siegal GP. Characterization of CXCR4 expression in chondrosarcoma of bone. Arch Pathol Lab Med. 2011;135:753-8.
  20. de Nigris F, Rossiello R, Schiano C, et al. Deletion of Yin Yang 1 protein in osteosarcoma cells on cell invasion and CXCR4/ angiogenesis and metastasis. Cancer Res. 2008;68:1797-808. https://doi.org/10.1158/0008-5472.CAN-07-5582
  21. Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res. 2002;62:7203-6.
  22. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 2004;14:171-9. https://doi.org/10.1016/j.semcancer.2003.10.003
  23. Gobert M, Treilleux I, Bendriss-Vermare N, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infi ltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009;69:2000-9. https://doi.org/10.1158/0008-5472.CAN-08-2360
  24. von Luettichau I, Nathrath M, Burdach S, Huss R, Segerer S, Nelson PJ. Mononuclear infi ltrates in osteosarcoma and chemokine receptor expression. Clin Cancer Res. 2006;12:5253-4. https://doi.org/10.1158/1078-0432.CCR-06-0785
  25. Takenaga M, Tamamura H, Hiramatsu K, et al. A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochem Biophys Res Commun. 2004;320:226-32. https://doi.org/10.1016/j.bbrc.2004.05.155
  26. Kim SY, Lee CH, Midura BV, et al. Inhibition of the CXCR4/ CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis. 2008;25:201-11. https://doi.org/10.1007/s10585-007-9133-3